ROIV - Roivant Sciences • Financials

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year	Revenue	EBITDA	Net Inc	Net Mrg	EPS	Equity	ROE	Net Debt Aj	ND/EBITDA Aj	OCF Aj	Capex	FCF	Free Aj	Buyback	Dividend	Payout	DY
03/2019	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
03/2020	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
03/2021	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
03/2022	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
03/2023	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
03/2024	33	4,519	-	13,000%	5.2	5,969	73%	-6,495	-	-965	-1	419	-966	-38	0	-	-
03/2025	29	-989	-	L	L	4,688	L	-4,887	-	-1,128	-5	-1,220	-1,133	-1,330	0	-	-
03/2026	8	-512	-	L	L	4,527	L	-4,292	-	-1,097	-8	134	-1,105	-367	0	-	-

To see all financials—including updated, you must be Premium.